How the Emmys Made Netflix’s Very Good Week Even Better
When the Emmy nominations were announced on Thursday, there were any number of people who were hoping Netflix’s already excellent week would end with a fizzle.
The old school broadcast networks (ABC, CBS, NBC and Fox), HBO, Amazon, Hulu, AMC, BBC America and FX all had shows that were widely admired and due for recognition at the annual awards extravaganza.
Netflix, on the other hand, was coming off the widely panned season of “House of Cards,” the critically admired but little-seen “Bloodline” and “Unbreakable Kimmy Schmidt,” and the domestic flop of its $90 million historical epic, “Marco Pollo.” Additionally, “Orange Is the New Black,” which had a strong third season both in terms of reviews and ratings, was forced by a change in the Emmy rules to submit as a drama rather than a comedy, putting it up against more hard-hitting dramatic programs.
Related: How the Video Game Industry Is Failing Its Fans
As it turns out, Netflix’s very good week would keep going with a record setting 34 nominations. This is dwarfed by HBO’s 127 nominations, but this is a remarkable number for the streaming service nevertheless.
The shower of nominations came on the end of a week in which Netflix stock price continued to climb at a rapid pace, making it the single best performing stock in the S&P 500 this year. Netflix continues to grow rapidly, adding 900,000 domestic users in Q2 and a staggering 2.4 million users internationally, widely exceeding expectations of 6000,000 and 1.9 million, respectively.
If there is a downside, it is that Netflix is unlikely to actually WIN in any of the major Emmy categories. The beloved series “Mad Men” and “Parks and Recreation” should have a lock on the comedy and drama awards (and if Jonathan Banks of “Better Call Saul” doesn’t win besting supporting actor in a drama, there will be riots!). But for Netflix, it is still an honor just to be nominated.
The streaming giant will not be resting on its laurels. Coming on the back of its critically-acclaimed and bone-crunching adaptation of “Daredevil,” the company will be teaming up with Marvel again for three more shows. Netflix will also be amping up its feature film division with debuts from “True Detective” director Cary Fukunaga and an action movie starring Brad Pitt.
The company may walk away empty handed when they hand out the golden statues on September 20th, but for the time being, everything is coming up Netflix.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.